Try our Advanced Search for more refined results

In Re: National Prescription Opiate Litigation

Track this case

Case Number:

1:17-md-02804

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. September 06, 2019

    Mallinckrodt Pays $24M To Exit Opioid MDL Bellwethers

    Mallinckrodt said Friday it will pay $24 million and donate up to $6 million in generic drugs to resolve claims from two Ohio counties that are behind the lead bellwether cases in multidistrict litigation against opioid manufacturers.

  2. September 05, 2019

    4 Key Takeaways As Ohio AG Fires Torpedo At Opioid MDL

    Ohio's attorney general is making an eleventh-hour bid to block the first bellwether trial in multidistrict litigation pitting local governments against opioid makers and distributors, but to do so, he must first clear a high bar in showing the state government will be harmed by a trial it is not party to. Here, Law360 explores four key takeaways from the attorney general’s surprise gambit.

  3. September 04, 2019

    Whether Opioid Crisis Is 'Public Nuisance' Up To Jury: Judge

    A jury will decide whether, under Ohio law, the opioid epidemic constitutes an "ongoing public nuisance," an Ohio federal judge ruled Wednesday in the multidistrict opioid litigation's lead bellwether cases, finding that underlying factual issues must first be determined at trial.

  4. September 03, 2019

    Opioid MDL Jury Will Weigh 'Complete Failures' By Drug Cos.

    A jury could find that "complete failures" by drug companies to stop illicit painkiller shipments unleashed a harrowing epidemic of addiction, an Ohio federal judge ruled Tuesday in the multidistrict opioid litigation's lead bellwether cases.

  5. August 30, 2019

    Ohio AG Asks 6th Circ. To Halt Upcoming Opioid Bellwether

    Ohio's attorney general on Friday urged the Sixth Circuit to halt an upcoming bellwether trial that's part of multidistrict litigation against drugmakers blamed for the opioid crisis, calling the claims made by two Buckeye State counties in the bellwether case an "intrusion onto sovereign territory."

  6. August 30, 2019

    Allergan To Pay $5M To Exit Ohio Opioid Bellwethers

    Allergan PLC on Friday said it had reached a $5 million settlement with two Ohio counties that are behind the lead bellwether cases in multidistrict opioid litigation.

  7. August 29, 2019

    Judge Limits Opioid MDL Experts On Compliance, Marketing

    The Ohio federal judge overseeing multidistrict litigation over the opioid crisis on Thursday barred expert testimony about the drugmakers' compliance programs, shortly after excluding other experts from testifying that marketing by Purdue, Johnson & Johnson and others caused more sales.

  8. August 20, 2019

    Endo Pays $10M To Exit Opioid MDL Bellwethers

    Endo Pharmaceuticals Inc. on Tuesday announced it will pay $10 million and donate up to $1 million in prescription drugs to exit the lead bellwether cases in multidistrict opioid litigation.

  9. August 19, 2019

    Lead Attys Approved For Opioid MDL 'Negotiation Class'

    The Ohio federal judge supervising multidistrict opioid litigation approved lead attorneys Monday for a proposed "negotiation class" of local governments that would pursue nationwide settlements with drug companies accused of sparking a devastating addiction crisis.

  10. August 08, 2019

    What We Know About Opioid MDL Settlement Talks

    Twenty months after the kickoff of multidistrict opioid litigation, lawyers close to the historic legal showdown say settlement talks are nowhere near the end zone. But they may be poised for a shot of adrenaline from a looming trial date and a novel "negotiation class" plan.

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!